The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: A meta-analysis

American Journal of Gastroenterology

Volumn 109, Issue 3, 2014, Pages 325-334

  Singal, Amit G ^a,b,e   Manjunath, Hema ^a   Yopp, Adam C ^a,b   Beg, Muhammad S ^a   Marrero, Jorge A ^a,b   Gopal, Purva ^a   Waljee, Akbar K ^c,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PROGNOSIS; CANCER RISK; CAUCASIAN; DISEASE COURSE; DISEASE SEVERITY; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PNPLA3 GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIPASE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MEMBRANE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; RISK FACTORS;

EID: 84895792814     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.476     Document Type: Article

References (60)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
2. Fattovich G, Stroff olini T, Zagni I et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-50.
3. Nishida N, Kudo M. Recent advancements in comprehensive genetic analyses for human hepatocellular carcinoma. Oncology 2013; 84 (Suppl 1): 93-7.
4. Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-5.
5. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148 M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883-94.
6. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-9, W64.
7. Wells GA, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. In: 3rd Symposium on Systematic Reviews: Beyond the Basics 2000.
8. Herzog R, Alvarez-Pasquin MJ, Diaz C et al. Are healthcare workers'intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. BMC Public Health 2013; 13: 154.
9. Higgins JP, Th ompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
10. Higgins JP, Th ompson SG, Deeks JJ et al. Measuring inconsistency in metaanalyses. BMJ 2003; 327: 557-60.
11. Copas JB, Shi JQ. A sensitivity analysis for publication bias in systematic reviews. Stat Methods Med Res 2001; 10: 251-65.
12. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat Med 2001; 20: 641-54.
13. Burlone M, Rossini A, Magri A et al. A composite score including BMI, liver stiff ness, and rs738409 PNPLA3 genotype might spare liver biopsies to most NAFLD patients maintaining 95% diagnostic accuracy. Hepatology 2012; 56: 885A.
14. Dunn W, Zeng Z, O'Neil M et al. The interaction of rs738409, obesity, and alcohol: a population-based autopsy study. Am J Gastroenterol 2012; 107: 1668-74.
15. Guichelaar M, Gawrieh S, Olivier M et al. Interactions of allelic variance of PNPLA3 with non genetic factors in predicting NASH and non-hepatic complications of severe obesity. Obesity 2013; 21: 1935-41.
16. Hotta K, Yoneda M, Hyogo H et al. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Med Genet 2010; 11: 172.
17. Krawczyk M, Grunhage F, Zimmer V et al. Variant adiponutrin (PNPLA3) represents a common fibrosis risk gene: non-invasive elastography-based study in chronic liver disease. J Hepatol 2011; 55: 299-306.
18. Miyashita M, Ito T, Sakaki M et al. Genetic polymorphism in cyclooxygenase-2 promoter aff ects hepatic inflammation and fibrosis in patients with chronic hepatitis C. J Viral Hepat 2012; 19: 608-14.
19. Müller T, Buch S, Berg T et al. Distinct, alcohol-modulated Effects of PNPLA3 genotype on progression of chronic hepatitis C. J Hepatol 2011; 55: 732-3.
20. Patin E, Kutalik Z, Guergnon J et al. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology 2012; 143: 1244-1252.e2.
21. Payer B, Reiberger T, Stift J et al. Influence of PNPLA3 SNP on hepatic steatosis and fibrosis progression in HIV-HCV coinfected patients. J Hepatol 2012; 56: S356.
22. Rotman Y, Koh C, Zmuda JM et al. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010; 52: 894-903.
23. Stattermayer A, Rutter K, Hofer H et al. PNPLA3 polymorphism is patients with chronic hepatitis C-impact on steatosis, fibrosis, and treatment response. J Hepatol 2011; 54: S194.
24. Stickel F, Buch S, Lau K et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology 2011; 53: 86-95.
25. Trepo E, Gustot T, Degre D et al. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J Hepatol 2011; 55: 906-12.
26. Trepo E, Pradat P, Potthoff A et al. Impact of patatin-like phospholipase-3 (rs738409 C > G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 2011; 54: 60-9.
27. Valenti L, Maggioni P, Piperno A et al. Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis. World J Gastroenterol 2012; 18: 2813-20.
28. Valenti L, Nobili V, Al-Serri A et al. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. J Hepatol 2011; 55: 1409-14.
29. Valenti L, Rumi M, Galmozzi E et al. Patatin-like phospholipase domaincontaining 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 2011; 53: 791-9.
30. Vigano M, Valenti L, Lampertico P et al. PNPLA3 I148M aff ects liver steatosis in patients with chronic hepatitis B. Hepatology 2013; 58: 1245-52.
31. Way M, McQuillin A, Gurling H et al. The PNPLA3 I148M mutation significantly increases the risk of developing alcohol-related cirrhosis in alcohol dependent individuals. J Hepatol 2013; 58: S563.
32. Zain SM, Mohamed R, Mahadeva S et al. A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease. Hum Genet 2012; 131: 1145-52.
33. Zampino R, Coppola N, Cirillo G et al. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. J Viral Hepatitis 2013; 20: 517-23.
34. Idilman R, Keskin O, Karatayli SC et al. The impact of genetic variability of patatin-like phospholipase domain-containing 3 gene on histological progression of non-alcoholic fatty liver disease: A crosssectional and longitudinal follow-up study. Hepatology 2012; 56: 884A-5A.
35. Rembeck K, Maglio C, Lagging M et al. PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. BMC Med Genet 2012; 13: 82.
36. Stattermayer AF, Rutter K, Beinhardt S et al. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. J Hepatol 2012; 57: 492-8.
37. Francque SM, Verrijken A, Mertens I et al. Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clin Gastroenterol Hepatol 2012; 10: 1162-8; quiz e87.
38. Verrijken A, Beckers S, Francque S et al. A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population. Obesity 2013; 21: 2138-45.
39. Tian C, Stokowski RP, Kershenobich D et al. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 2010; 42: 21-3.
40. Clark PJ, Th ompson AJ, Zhu Q et al. The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection. Dig Dis Sci 2012; 57: 2213-21.
41. Corradini SG, Burza MA, Molinaro A et al. Patatin-like phospholipase domain containing 3 sequence variant and hepatocellular carcinoma. Hepatology 2011; 53: 1776; author reply 1777.
42. Falleti E, Fabris C, Cmet S et al. PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver Int 2011; 31: 1137-43.
43. Guyot E, Sutton A, Rufat P et al. PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis. J Hepatol 2013; 58: 312-8.
44. Hamza S, Petit J, Masson D et al. PNPLA3 rs738409 GG homozygote status is associated with increased risk of hepatocellular carcinoma in cirrhotic patients. J Hepatol 2012; 56: S281.
45. Liu Y, Patman G, Lethart J et al. Carriage of PNPLA3 I148M is associated wtih an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 2013; 58: S516.
46. Nischalke HD, Berger C, Luda C et al. The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS ONE 2011; 6: e27087.
47. Takeuchi Y, Ikeda F, Moritou Y et al. The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis. J Gastroenterol 2013; 48: 405-12.
48. Trepo E, Guyot E, Ganne-Carrie N et al. PNPLA3 (rs738409 C > G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis. Hepatology 2012; 55: 1307-8.
49. Burza MA, Pirazzi C, Maglio C et al. PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals. Dig Liver Dis 2012; 44: 1037-41.
50. Valenti L, Motta B, Soardo G et al. I148M PNPLA3 polymorphism is associated with clinical features in patients wtih hepatocellular carcinoma. J Hepatol 2012; 56: S129.
51. He S, McPhaul C, Li JZ et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010; 285: 6706-15.
52. Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem 2011; 286: 37085-93.
53. Valenti L, Dongiovanni P, Ginanni Corradini S et al. PNPLA3 I148M variant and hepatocellular carcinoma: A common genetic variant for a rare disease. Dig Liver Dis 2013; 45: 619-24.
54. Valenti L, Aghemo A, Stattermayer AF et al. Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. Aliment Pharmacol Th er 2013; 35: 1434-42.
55. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-32.
56. Singal AG, Mukherjee A, Elmunzer BJ et al. Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma. Am J Gastroenterol 2013; 108: 1723-30.
57. Singal AG, Tiro JA, Gupta S. Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening. Clin Gastroenterol Hepatol 2013; 11: 472-7.
58. Singal AG, Yopp A, C SS et al. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med 2012; 27: 861-7.
59. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
60. Weston SR, Leyden W, Murphy R et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005; 41: 372-9.